NVCT - Nuvectis Pharma Inc
9.65
0.570 5.907%
Share volume: 94,855
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.17%
PREVIOUS CLOSE
CHG
CHG%
$9.08
0.57
0.06%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-07-2024 | 08-06-2024 | 11-05-2024 | 02-25-2025 | 05-06-2025 | 11-04-2025 | 02-11-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 4.396 M | 4.643 M | 4.359 M | 6.449 M | 5.568 M | 7.794 M | 7.617 M | |
| Selling general and admin | 1.736 M | 1.700 M | 1.540 M | 1.953 M | 1.888 M | 2.020 M | 2.531 M | |
| Research and development | 2.660 M | 2.943 M | 2.819 M | 4.496 M | 3.680 M | 5.774 M | 5.086 M | |
| Total expenses | 4.396 M | 4.643 M | 4.359 M | 6.449 M | 5.568 M | 7.794 M | 7.617 M | |
| 5.62% | -6.12% | 47.95% | -13.66% | 39.98% | -2.27% | |||
| Operating income | -4.396 M | -4.643 M | -4.359 M | -6.449 M | -5.568 M | -7.794 M | -7.617 M | |
| Ebit | -4.171 M | -4.428 M | -4.153 M | -6.449 M | -5.568 M | -7.794 M | -7.617 M | |
| Pretax income | -4.171 M | -4.428 M | -4.153 M | -6.248 M | -5.332 M | -7.462 M | -7.314 M | |
| 6.16% | -6.21% | 50.45% | -14.66% | 39.95% | -1.98% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -4.171 M | -4.428 M | -4.153 M | -6.248 M | -5.332 M | -7.462 M | -7.314 M | |
| -6.16% | 6.21% | -50.45% | 14.66% | -39.95% | 1.98% |